ondansetron has been researched along with Colonic Diseases, Functional in 9 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Colonic Diseases, Functional: Chronic or recurrent colonic disorders without an identifiable structural or biochemical explanation. The widely recognized IRRITABLE BOWEL SYNDROME falls into this category.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ondansetron is a selective 5-hydroxytryptamine(3) (5-HT(3)) receptor antagonist that has been introduced to clinical practice as an antiemetic for cancer treatment-induced and anesthesia-related nausea and vomiting." | 4.81 | Ondansetron: a selective 5-HT(3) receptor antagonist and its applications in CNS-related disorders. ( Ponnudurai, R; Schaefer, R; Ye, JH, 2001) |
| "The use of ondansetron, a selective serotonin 5-HT3 receptor antagonist, is well established in patients with nausea and vomiting associated with cancer chemotherapy, radiotherapy or anaesthesia and surgery." | 4.79 | Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications. ( Markham, A; Wilde, MI, 1996) |
| "Alosetron (Lotronex) is a serotonin subtype 3 (5-HT3) receptor antagonist that alleviates symptoms of irritable bowel syndrome (IBS) in female patients." | 1.31 | Effects of alosetron on spontaneous migrating motor complexes in murine small and large bowel in vitro. ( Bush, TG; Sanders, KM; Smith, TK; Spencer, NJ; Watters, N, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (77.78) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kishibayashi, N | 1 |
| Miwa, Y | 1 |
| Hayashi, H | 1 |
| Ishii, A | 1 |
| Ichikawa, S | 1 |
| Nonaka, H | 1 |
| Yokoyama, T | 1 |
| Suzuki, F | 1 |
| Zighelboim, J | 1 |
| Talley, NJ | 3 |
| Phillips, SF | 3 |
| Harmsen, WS | 1 |
| Zinsmeister, AR | 2 |
| Hammer, J | 1 |
| Camilleri, M | 1 |
| Maxton, DG | 1 |
| Morris, J | 1 |
| Whorwell, PJ | 1 |
| Wilde, MI | 1 |
| Markham, A | 1 |
| Farthing, MJ | 1 |
| Ye, JH | 1 |
| Ponnudurai, R | 1 |
| Schaefer, R | 1 |
| Bush, TG | 1 |
| Spencer, NJ | 1 |
| Watters, N | 1 |
| Sanders, KM | 1 |
| Smith, TK | 1 |
| Steadman, CJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison Between Ondansetron 8 mg and Lidocain 40 mg in Preventing Pain Due to Propofol Injection[NCT03134612] | Phase 2 | 104 participants (Actual) | Interventional | 2016-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for ondansetron and Colonic Diseases, Functional
| Article | Year |
|---|---|
Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications.
Topics: Animals; Antiemetics; Brain; Colonic Diseases, Functional; Digestive System; Drug Interactions; Drug | 1996 |
New drugs in the management of the irritable bowel syndrome.
Topics: Adult; Anti-Anxiety Agents; Antidepressive Agents; Antidiarrheals; Benzyl Compounds; Colonic Disease | 1998 |
Ondansetron: a selective 5-HT(3) receptor antagonist and its applications in CNS-related disorders.
Topics: Animals; Colonic Diseases, Functional; Humans; Ion Channels; Nausea; Ondansetron; Receptors, Seroton | 2001 |
4 trials available for ondansetron and Colonic Diseases, Functional
| Article | Year |
|---|---|
Visceral perception in irritable bowel syndrome. Rectal and gastric responses to distension and serotonin type 3 antagonism.
Topics: Adult; Cold Temperature; Colonic Diseases, Functional; Double-Blind Method; Female; Humans; Male; Mi | 1995 |
Effect of a 5HT3-antagonist (ondansetron) on rectal sensitivity and compliance in health and the irritable bowel syndrome.
Topics: Adult; Colon; Colonic Diseases, Functional; Defecation; Female; Humans; Male; Ondansetron; Pressure; | 1993 |
Selective 5-hydroxytryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia?
Topics: Adult; Aged; Colonic Diseases, Functional; Cross-Over Studies; Defecation; Double-Blind Method; Dysp | 1996 |
Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: a pilot study.
Topics: Adult; Aged; Colonic Diseases, Functional; Diarrhea; Double-Blind Method; Female; Gastrointestinal H | 1992 |
2 other studies available for ondansetron and Colonic Diseases, Functional
| Article | Year |
|---|---|
5-HT3 receptor antagonists. 3. Quinoline derivatives which may be effective in the therapy of irritable bowel syndrome.
Topics: Animals; Carboxylic Acids; Castor Oil; Colon; Colonic Diseases, Functional; Defecation; Diarrhea; Di | 1993 |
Effects of alosetron on spontaneous migrating motor complexes in murine small and large bowel in vitro.
Topics: Animals; Carbolines; Colon; Colonic Diseases, Functional; Disease Models, Animal; Dose-Response Rela | 2001 |